ODAIA has closed a US$15 million Series C, according to the ODAIA funding release dated November 17, 2026. Monograph Capital led the round. PHM, the U.S. health media agency owned by Publicis Groupe, anchored it as a strategic investor and also signed a platform agreement that makes it ODAIA’s exclusive agency partner in the U.S.

The company spun out of the University of Toronto in 2018, is headquartered in Toronto and has an office in Boston. It sells predictive AI to pharmaceutical commercial teams. The software flags physicians whose patients are likely to need a particular therapy, then ranks which ones field reps and marketers should contact first and through which channel.

BetaKit put the round at about CA$21 million. Six existing investors came back, InfoTechLead’s report on the round confirms. BDC Capital, Flint Capital, Innospark Ventures and Graphite Ventures backed the Series A. Threshold Ventures and Wittington Ventures joined in the Series B. The release doesn’t say how much any single investor put in, PHM included, and gives no valuation.

ODAIA says the money will go to two things: selling more into the enterprise pharma accounts it already serves, and building out its platform. For those customers, the PHM deal is the bigger change. PHM will offer ODAIA’s software to the drug brands it works with, tying digital media buying to field sales planning for the doctors those brands target.

“Pharma has proven that AI works in commercial. The hard part now is scaling it.”

Philip Poulidis, CEO and co-founder of ODAIA

Pharma isn’t the only buyer asking whether AI pays for itself. Nebuly raised a $21 million Series A to measure the return on enterprise AI.

What does a smaller Series C tell you?

Here are the last two rounds, using ODAIA’s own announcements:

  • Series B, announced May 1, 2023: US$25 million, co-led by Threshold Ventures and Monograph Capital
  • Series C, announced November 17, 2026: US$15 million, led by Monograph Capital and anchored by PHM

The new round is $10 million smaller ($25 million minus $15 million), which works out to 40% less (10 ÷ 25). The two rounds together come to $40 million.

That’s 40% less money, 42 months later.

The figures alone don’t tell you why. A smaller late-stage round can mean the company needed less cash or that less was on offer, and without a valuation you can’t tell whether this one priced up or down. ODAIA also gave no revenue figure and no customer count. Look for two numbers next: how many brands PHM actually signs onto the platform, and whether ODAIA ever puts a price on this round. Other healthcare buyers are spending on AI too. Little Apple Pediatrics closed a strategic round to build AI into its 10 clinics.

Emma writes about corporate change for Companies History, covering mergers, acquisitions, spin-offs, rebrands, and turnarounds. Her articles look closely at the decisions behind each change and how the business fared afterward, offering lessons from both success stories and failures.